Antibody specialist Nona Biosciences, a wholly-owned subsidiary of Hong Kong-based HBM Holdings (HKEX: 02142), has entered into an exclusive license agreement with Pfizer (NYSE: PFE).
The deal will facilitate the global clinical development and commercialization of Nona’s MSLN-targeted antibody-drug conjugate (ADC), HBM9033.
Under the terms of the deal, Nona will receive a total of up to $53 million in upfront and near-term payments, with the potential for additional payments of up to $1.05 billion in milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze